Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Antiplatelet agents under research at Monsanto

March 1, 1999

Spotlight update: fibrinogen (gpIIb/IIIa) receptor antagonists

March 1, 1999

Orally active TxA2 antagonist in clinical development at Zeria

Feb. 25, 1999

Four U.S. patents provide additional protection for Corvas's rNAP program

Feb. 24, 1999

Abciximab improves microvascular perfusion after stenting in acute myocardial infarction

Feb. 24, 1999

Activase for acute management of stroke approved in Canada

Feb. 22, 1999

Astra's P2T receptor antagonists offer significant potential as novel antithrombotics

Feb. 19, 1999

Boehringer Ingelheim researches thrombin inhibitors

Feb. 19, 1999

New series of anticoagulants for oral administration developed at Lilly

Feb. 18, 1999

Another European market opens up to desirudin

Feb. 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...